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This manuscript describes the synthesis of new Au(I) and Ag(I) complexes with 
aminophosphane ligands and a study of their antibacterial activity against Gram-
negative Salmonella enterica serovar typhimurium and Escherichia coli and Gram-
positive Listeria monocytogenes and Staphylococcus aureus. The bactericidal assays 
revealed the effectiveness of these compounds on paradigm Gram-negative and Gram-
positive pathogens, showing a moderate antimicrobial activity, comparable with the 
antibiotics of reference, for all gold(I) complexes and the silver(I) complexes without 
coordinated PPh3 groups. For those complexes that were found to show inhibitory 
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activity, serial dilutions in liquid broth method were performed for determination of 
MIC (minimum inhibitory concentration) and MBC (minimum bactericidal 
concentration). 
 





The use in medicine of penicillin in the 1940s, erythromycin in the 1950s and 
methicillin in the 1960s greatly contributed to control bacterial diseases. However, the 
extended and uncontrolled use of antibiotics soon brought the need for the development 
of new antimicrobial agents because of the rapid increase of bacterial resistance, 
decreasing antibiotic efficacy and complicating the treatment of infections. The 
acquired bacterial resistance to vancomycin was slower and required nearly thirty years 
to found antibiotic resistant strains [1]. Since then, a large number of transition metal 
compounds have been screened against bacteria and fungi. For gold(I), research has 
been principally focused on compounds with a SAuP or NAuP core, exploiting the 
analogy to Auranofin [2]. Studies have shown good bactericidal or bacteriostatic results 
[3-5], some of them including Auranofin and related complexes have shown as potent 
inhibitors of methicillin-resistant Staphylococcus aureus [6], and they also present 
antitumor, antimalarial, or antirheumatic activities [7]. Other important type of metal 
complexes presenting good antibacterial activity are those related to N-heterocyclic 
carbene ligands NHCs, especially silver but also gold complexes [8]. 
Silver(I) compounds also show a wide spectrum of effective antimicrobial activity. 
Silver nitrate has been used since the seventeenth century for the prevention of neonatal 
conjunctivitis and is still in use today [9]. The most commonly used silver compound is 
silver(I) sulfadiazine ([Ag((4-aminophenyl)sulfonyl)(pyrimidin-2-yl)azanide]n, which is 
widely used in medicine to treat and prevent the development of bacterial infections in 
skin burns [10]. Nowadays numerous silver(I) compounds with AgN, AgP or NAgP 
unit have been synthesized [11-14], and more recently AgC from NHCs [15,16] and 
have presented cytotoxic activity against Gram-positive and Gram-negative bacteria, 
although the mechanisms of action of silver(I) compounds are not completely 
understood.  
Infections caused by Gram-positive and Gram- negative bacteria are of major concern 
due to the increased incidence of drug resistant strains. The food-borne Salmonella 
typhimurium and Escherichia coli are the most prevalent Gram-negative pathogens in 
humans and animals. These bacteria cause enteric diseases that are commonly treated by 
β-Lactam antibiotics. However, the prolonged administration of these antibiotics have 
resulted in a striking correlation between drug use and the emergence of antibiotic 
resistant strains. β-Lactam antibiotics interfere with bacterial cell wall biosynthesis that 
eventually leads to cell death. The mechanism of action is to bind covalently to their 
targets, the penicillin-binding proteins (PBPs), enzymes involved in cell wall synthesis 
in the cytoplasmic membrane of the bacteria. Antibiotics penetrate the outer membrane 
of gram-negative bacteria through protein pores called porins. The acquired resistance 
to β-lactam antibiotics may be due to a range of diverse factors: mutations in the PBPs 
that reduce or prevent the binding to the antibiotic, porin mutations which preclude or 
reduce outer-membrane permeability [17], hyper-expression of efflux pumps that expel 
antibiotics outside the bacteria or β-lactamases produced by bacteria to cleave the 
antibiotic. The combination of these factors results in Gram-negative resistance to β-
Lactam antibiotics [18, 19]. 
With regard to Gram-positive organisms, Listeria monocytogenesis is a food-borne 
human pathogen responsible for listeriosis, a disease that although not common in 
healthy people, can cause severe diseases including abortions and meningitis. The 
number of listeriosis cases has increased in recent years in several industrialized 
countries [20-23] and although treatment with ampicillin or penicillin in combination 
with gentamicin (or other aminoglycoside) [24] is effective, the recent increase in 
antibiotic resistance is a concern. For example, strains N53-1 and 4446 are resistant to 
gentamicin and other aminoglycosides, and some strains are able to persist within 
different types of food processing plants for years and consequently are repeatedly 
exposed to biocides, something that could potentially impact on bacterial resistance [25- 
28].  
Staphylococcus aureus is another Gram-positive bacteria causative of serious hospital-
acquired infections. Nowadays strains with intermediate levels of resistance to 
vancomycin or even resistant appear more frequently [29]. One reason for this could be 
the bifunctional acetyltransferase(6')-Ie-phosphotransferase(2'')-Ia[AAC(6')-Ie-
APH(2'')-Ia], the most important aminoglycoside-resistance enzyme in Gram-positive 
bacteria, that confers resistance to almost all known aminoglycoside antibiotics in 
clinical use [30]. However resistance is not only related to aminoglycoside antibiotics 
like vancomycin, there are S. aureus strains resistant to methicillin that are also resistant 
to practically all β-Lactam group (penicillin, oxacillin, ampicillin, amoxicillin and 
augmentin), and macrolides (clindamycin and azithromycin). These multidrug-resistant 
strains are spreading outside hospitals and represent a serious concern [31] and sensitive 
to the aminoglycoside group (amikacin), macrolide antibiotics (nitrofurantoin) and the 
quinolone group (ciprofloxacin, ofloxacin and norfloxacin) [32-35]. 
In this work we describe the synthesis and structural characterization of new gold and 
silver complexes with aminophosphane ligands. These ligands were chosen because 
other phosphane-gold derivatives are known to have antibacterial activity and because 
the presence of the amine group allows and easy functionalisaton, making possible the 
introduction of relevant biological moieties. These compounds were tested in vitro to 
study their activity against Gram-negative S. typhimurium SV5015 and E. coli ATCC 
10536 strains and the Gram-positive L. monocytogenes EGD-e and S. aureus ATCC 
11632 strains using the paper disc diffusion method (for the qualitative determination) 
and for those complexes that were found to show inhibitory activity, serial dilutions in 
liquid broth method were performed (for determination of MIC (minimum inhibitory 
concentration) and MBC (minimum bactericidal concentration)).This paper is a 
continuation of a previous study using the same ligand [36], in which the susceptibility 
of (aminophosphane)gold(I) thiolate complexes against Enterococcus faecalis ATCC 
25923, S. aureus ATCC 29213 and E. coli TG1 was demonstrated. Some of them were 
found to exhibit powerful antibacterial activity, being more efficient against Gram-
positive microorganisms. 
2. Results and discussion 
 
2.1. Synthesis and Characterization 
 
Herein we report the synthesis and characterization of a series of gold(I) and silver(I) 
derivatives with two different aminophosphane ligands: 2-
(diphenylphosphanylamino)pyridine (Ph2PNHpy) (Scheme 1) and 3-
(diphenylphosphanylamino)-1,2,4-triazole [Ph2PNH(Htrz)] (Scheme 2) [37]. 
Spectroscopic characterizations of the metal complexes were performed using IR, ESI+ 






In the ESI+ (positive mode of electrospray ionization) mass spectra of 3-6, 8, 9, 12 and 
14 the cation peaks [M-OTf]+ are observed and in 10 the protonated molecular peaks [M 
+ H]+ are seen. The IR spectra of 2 and 11 show the bands corresponding to the 
presence of the pentafluorophenyl groups bonded to the gold atom. Their 19F{1H} NMR 
spectra show three signals corresponding to ortho, meta and para fluorine atoms, 
respectively, of the pentafluorophenyl ring with small shifts compared to the starting 
material [Au(C6F5)(tht)] (tht = tetrahydrothiophene). The 1H NMR spectra of the 
compounds in d6-DMSO or d6-acetone present the expected resonances for all of the 
protons (see experimental section) and show a low or high-field shift of the aromatic 
protons indicatives of the successful coordination of the metal to the ligand through the 
phosphorus (1-5,10-12) or the phosphorus and the nitrogen atom (6-9,13-14). The 1H 
NMR spectra of complexes 3, 4, 8 and 9 show the corresponding phosphine group 
signal, indicative of the coordination of one or two phosphine group. The 31P{1H} NMR 
spectra provide a great deal of information about the present series of complexes. The 
gold compounds show single resonances 54.0 (1), 65.3 (2), 64.8 (3), 64.8 (4), 62.3 (5), 
54.0 (10), 68.9 (11), 68.7 (12) significantly downfield relative to their precursors, 25.5 
(L1) or 36.9 (L2). The silver 31P{1H} NMR spectra at room temperature display one 
broad signal for complexes 6, 7, 13 and 14 or two broad resonances for complexes 8 
and 9. At 203 K the 31P{1H} NMR spectra of complexes 6, 7 and 14 show two doublets 
due to coupling with 107Ag and 109Ag nuclei. The 31P{1H} NMR spectrum at 203 K of 
complex 9 shows signals that correspond to an AB2 system: two doublets centered at 9.9 
and 9.3 ppm and two multiplets centered at 23.9 and 21.8 ppm. At 203 K complex 8 
shows a complicated spectrum with two groups of signals: one that appears to 
correspond to an AB2 system, with equal shifts to complex 9 and other that appears to 
correspond to complex 7. With the information obtained from 31P{1H} NMR studies at 
low temperature we propose the existence in solution of complex 8  as an equilibrium 
between two species, one without a PPh3 group (7) and the other with two PPh3 groups 
(9) (Figure 1) [14, 38-42]. 
Fig. 1 
The reaction between L2 and [Au(tht)2](OTf) in a 2:1 ratio or [Au(OTf)(PR3)] (R3 = 
PPh3, PPh2py) in a 1:1 ratio gave complex (12). In the 1H NMR spectra we find the 
expected displaced resonances for the ligand L2 protons but the corresponding 
phosphine group signal in the reaction with [Au(OTf)(PR3)] (R3 = PPh3, PPh2py) do not 
appear. The 31P{1H} NMR spectra show a signal significantly downfield relative to the 
precursor L2. 
 
2. 2. Crystal structure description 
 
We confirmed the molecular structures of complexes 6, 9 and 10 by an X-ray 
crystallographic study, although the last one was previously published [36]. Complex 6 
(Figure 2) crystallizes in a monoclinic system with two independent units in the 
asymmetric unit. There are no important geometric differences between the two 
independent molecules, which shown similar Ag-N and Ag-P bond distances and these 
are also comparable to those found in other derivatives with the same N-Ag-P core 
where the silver atom is in tetracoordinated around. Both silver atoms are in a highly 
distorted tetrahedral geometry caused by the aminophosphane ligand that forces 
chelation angles from 75.74(6)º to 77.29(6)º.  
There are several hydrogen bond in the molecule involving the oxygen of the triflate 
anions as an acceptor and the protons of the amide group (NHpy) of the ligand as a 
donor of protons; in all the cases the angles D-H···A are close to 180º. 
 
Fig. 2 
The structure of complex 9 has also been established by X-ray diffraction and the 
molecule can be seen in Fig. 3. The geometry around the silver center is tetrahedral with 
the main distorsion arising from the bite angle of the phosphinoamine, 74.99(12)º. The 




All the complexes synthesized were tested for their in vitro antibacterial activity against 
Gram-negative bacteria S. typhimurium SV5015 and E. coli ATCC 10536 and Gram-
positive L. monocytogenes EGD-e and S. aureus ATCC 11632. Ampicillin, kanamycin, 
gentamicin, chloramphenicol, vancomycin, erythromycin and rifampicin were used as 
standard drugs for Gram-positive and/or Gram-positive bacteria. Structures of these 
drugs are shown in Figure 4. 
Fig. 4 
The qualitative determination for the complexes studied is presented in Tables 1 and 2. 
Our previous report shows that the ligands have no bactericidal activity, whereas some 
of the metal complexes show activity under identical experimental conditions. 
All the compounds were insoluble in water and the assay was carried out using DMSO 
as solvent. The solvent DMSO (in the same percentage used to dissolve the compounds) 
was also used as a control to confirm that it did not inhibit bacterial growth. The results 






In the qualitative determination it was not possible to screen the activity of complexes 2, 
5, and 12 due to solubility problems. None of the silver(I) and gold(I) compounds 
studied were effective against Gram-negative bacteria (Table 1), however the results 
were different for Gram-positive bacteria (Table 2) with the complexes showing 
biological activity.  Figure 5 shows zones of bacterial growth inhibition for some of the 







The different antibacterial behavior of complexes might be related to the cell wall, since 
this is the first structural difference between Gram-positive and Gram-negative bacteria 
that represents the primary target for antimicrobial agents. Gram-positive bacteria 
possess a thick cell wall of peptidoglycan whereas Gram-negative bacteria have a thin 
cell wall of peptidoglycan surrounded by a second lipid membrane containing 
lipopolysaccharides and lipoproteins. Hence, it is tempting to speculate that the different 
bactericidal behavior of compounds can be explained by their ability to pass through the 
membrane and somehow interact; producing changes that eventually cause the death of 
the bacteria [43, 44]. The interaction is based on the strong attraction of positively 
charged compounds. If compounds can form bond complexes or interact 
electrostatically with the cell wall, it is very probable that the compound will possess 
biocide activity. This phenomenon occurs more readily with Gram-positive bacteria 
because the pores of peptidoglycan cell wall are not efficient barriers for the compounds 
of determined size [45]. Furthermore, it has been shown that some pyrazine 
functionalized Ag(I) and Au(I)-NHC complexes strongly binds both Lys and Dap-type 
peptidoglycan layers, which may be the reason for damage to the bacterial cell wall. 
[46]. 
 
The negative bactericidal results of silver(I) complexes are in agreement with previous 
studies that explain that Ag(I)-P complexes show no activity, very likely because there 
is no exchange with biomolecules. The antimicrobial properties of silver(I) complexes 
depend upon the fast rate of ligand exchange of the metal ion in the biological system 
(more than solubility, charge, chirality or degree of polymerization) and this correlates 
to the nature of the donor atoms coordinated to the silver [47-51]. The silver(I) 
compounds with weak Ag–O and Ag–N bonds exhibit a wider spectrum of antibacterial 
activity because they can more readily exchange their N- or O- ligands for O-, N-, S- 
donor atoms of amino acids or nucleotides [52]. Ag(I)–S complexes show a narrower 
spectrum of activity compared to Ag-N and Ag-O [53-55] and silver(I)–P complexes 
[56] have shown no activity against bacterial strains, yeast and molds [57].  Gold(I) 
results also are in agreement with results found in the literature. The complexes with a 
S-Au-P bond show better bactericidal properties against Gram-positive bacteria than 
those with an N-Au-P core [7,36] (Table 1 and 2). Gold(I) phosphine derivatives present 
no activity against E. coli and S. typhimurium (Table 1 and 2), although in some water 
soluble gold(I) phosphine complexes have been reported to have activity in these 
bacteria [58]. 
 
For the tested Gram-positive bacteria, results are positive. For L. monocytogenes, 
gold(I) compounds show bacterial activity and some of them present a bigger inhibitory 
zone compared with control antibiotics. Silver(I) compounds with L2 (13 and 14) 
present biological properties. Assays with S. aureus shows practically identical results 
to L. monocytogenes. Only one silver(I) compound (14) presents inhibitory activity and 
all gold(I) compounds show diameters of zones of inhibition larger than that of 
vancomycin, the only antibiotic used as reference that presented bactericidal activity in 
the strain. For both strains silver compounds without phosphine (PPh3) groups 
coordinated are the complexes showing antibacterial activity. Also, in the chemical 
discussion we present the existence in solution of equilibrium between 8 and 
compounds 9 and 7. If there is equilibrium, a similar bactericidal behavior of both 
complexes as we found in the study with Gram-positive bacteria is expected. 
It was determined the minimum inhibitory concentrations (MICs) and minimal 
bactericidal concentrations (MBCs) for complexes displaying zone inhibition in the disc 
diffusion method (Table 3). The results show that the majority of studied complexes 
displayed bacteriostatic activity as assessed by the lower MIC compared to the MBC 
values. In some cases where the MBC could be determined, the values were the same as 






A series of new silver(I) and gold(I) derivatives have been synthesized and 
characterized as a continuation of a previous research of gold(I) thiolate complexes 
using the same aminophosphane ligands. The bactericidal assays revealed the 
effectiveness of all the tested compounds on Gram-negative and in Gram-positive 
bacteria, showing a  moderate antimicrobial activity for all gold(I) complexes and the 
silver(I) derivatives without PPh3 groups coordinated, which is comparable to the 
reference antibiotics. These results confirm the influence of the atoms coordinated to the 
metal center found in the literature, and suggest that the mechanism for the antibacterial 
action might be related to the inhibition of peptidoglycan synthesis in the cell wall 
because of the specific selectivity to Gram-positive versus Gram-negative bacteria. This 
finding contributes to fill the pipeline of antimicrobial compounds that could be 
potentially useful to treat emerging drug resistant pathogens. 
  




Instrumentation: IR spectra were recorded in the range 4000–200 cm–1 with a Perkin–
Elmer Spectrum 100 spectrophotometer on solid samples by using an ATR accessory. 
C, H and N analyses were carried out with a Perkin–Elmer 2400 Series 2 microanalyser. 
Mass spectra were recorded with a VG Austopec by using the ESI technique. NMR 
spectra were recorded in [D6]DMSO, CDCl3 or (CD3)2CO solution, most of them with a 
Bruker ARX 400 spectrometer; some of the 13C{1H} NMR spectra were recorded with a 
Bruker ARX 300 spectrometer. Chemical shifts are cited relative to Syme4 (1H, 13C, 
external) and 85% H3PO4 (31P, external). Unfortunately, in the 13C{1H}NMR spectra of 
several complexes we did not observe all of the signals expected, probably as a 
consequence of the poor solubility of the complexes. 
 
4.1.1. Starting materials 
 
The phosphane ligands Ph2PNHpy (L1) and [Ph2PNH(Htrz)] (L2) [37], the gold(I) 
complexes [AuCl(Ph2PNHpy)] (2) and [AuCl{Ph2PNH(Htrz)}] (10) [37] and the 
starting materials [Au(C6F5)(tht)] [59], [Au(tht)2](OTf)] [60] and [Ag(OTf)(PPh3)] [61] 
were prepared according to published procedures. [Au(OTf)(PPh3)] was obtained by 
reaction of [AuCl(PPh3)] [62] with Ag(OTf) in dichloromethane and used in situ. All 
other reagents were commercially available and used without further purification. 
 
4.1.2. Synthesis of metal complexes  
 
Synthesis of [Au(C6F5)(PPh2NHpy)] (2) 
 
To a solution of L1 (0.055 g, 0.2 mmol) in 20 mL of dichloromethane was added 
[Au(C6F5)(tht)] (0.090 g, 0.2 mmol). The mixture was stirred for 1 h and then 
evaporation of the solvent to ca. 5 mL and addition of hexane gave complex 2 as a 
white solid. Yield: 0.093 g, 72.50 %. C23H15N2PF10 (642.31): calcd. C, 42.92; H, 2.23; 
N, 4.48, found C, 43.01; H, 2.35; N, 4.36. IR (cm-1): ν(NH) = 2978, ν(C=N) = 1602, 
ν(PN) = 911, ν(C6F5) 1500, 954, 800. 1H NMR (400 MHz, DMSO) δ: 8.84 (d, 1 H, NH, 
2JPH 3.9 Hz), 8.07 (m, 1 H, H6), 7.75 (m, 4 H, HPh), 7.63 (m, 7 H, HPh y 4), 7.03 (d, 1 H, 
H3, 3JHH 8.3 Hz), 6.88 (m, 1 H, H5). 31P{1H} NMR (400 MHz, DMSO) δ: 65.3 (s, 1P, 
PPh2). 19F NMR (400 MHz, DMSO) δ: (-114.59) (m, 2F, Fortho), (-158.43) (t, 1F, Fpara, 
Jmeta-para  21.2 Hz), (-161.74) (m, 2F, Fmeta). 
 
Synthesis of [Au(PR3)(PPh2NHpy)](OTf) (R3= Ph3 (3), Ph2py (4)). 
 
To a solution of L1 (0.055 g, 0.2 mmol) in 20 mL of dichloromethane was added 
[Au(OTf)(PPh3)] (0.127 g, 0.21 mmol) or [Au(OTf)(PPh2py)] (0.128 g, 0.21 mmol). 
The mixture was stirred for 2 h and then evaporation of the solvent to ca. 5 mL and 
addition of hexane gave complexes 3 and 4 as white solids.  
 
Complex 3. Yield: 0.147 g, 82.70 %. C36H30AuF3N2O3P2S (886.61): calcd. C, 48.77; H, 
3.41; N, 3.16; S, 3.62, found C, 49.32; H, 3.61, N, 3.29; S, 4.12. IR (cm-1): ν(NH) = 
3224, ν(C=N) = 1592, ν(PN) = 906, νasym(SO3) = 1273 y 1248, νsym(CF3) = 1218, 
νasym(CF3) = 1150, νsym(SO3) = 1028. 1H NMR (400 MHz, (CD3)2CO) δ: 7.78 (m, 1H, 
H6), 7.51 (m, 9H, HPh y 4), 7.31 (m, 11H, HPh), 7.04 (d, 1H, H3, 3JHH 8.3 Hz), 6.81 (m, 
1H, H5). 1H NMR (400 MHz, DMSO) δ: 8.99 (m, 1H, NH), 7.71 (m, 1H, H6), 7.62 (m, 
1H, H4), 7.45 (m, 14H, HPh), 7.18 (m, 3H, HPh), 6.93 (d, 1H, H3, 3JHH 8.2 Hz), 6.76 (m, 
1H, H5). 19F NMR (400 MHz, (CD3)2CO) δ: -80.03 (s, 1F, OTf). 31P{1H}NMR (400 
MHz, (CD3)2CO) δ: 64.8 (s, 1P, PPh2), 37.0 (s, 1P, PPh3). 13C{1H}NMR (400 MHz, 
DMSO) δ: 155.50 (s, 1C, C2), 146.84 (s, 1 C, C6), 138.25 (s, 1 C, C4), 133.69 (1 C, 
CCipsoPh, d, 1JCP 46.4 Hz), 133.08 (d, 1 C, CorthoPh, 2JCP 14.7 Hz), 131.09 (d, 1 C, CorthoPh, 
2JCP 38.1 Hz), 131.29 (s, 1 C, CCipsoPh), 128.89 (m, 3 C, CmetaPh,paraPh), 116.01 (s, 1 C, 
C5), 112.15 (s, 1 C, C3). MS (ESI+): m/z (%) = 737.3 ([M-OTf]+, 100), 752.2 
([(PPh2NHpy)2Au]+, 54.1). 
 
Complex 4. Yield: 0.142 g, 80.31%. C35H29AuF3N3O3P2S (887.60): calcd. C, 47.36; H, 
3.29; N, 4.73; S, 3.61, found C, 47.90; H, 3.61; N, 5.02; S, 3.62. IR (cm-1): ν(NH) 3189, 
ν(C=N) = 1590, ν(PN) = 910, νasym(SO3) = 1273 y 1248, νsym(CF3) = 1223, νasym(CF3) = 
1150, νsym(SO3) = 1028. 1H NMR (400 MHz, (CD3)2CO)) δ: 8.79 (d, 1H, H6’, 3JHH 4.5 
Hz), 8.27 (s br, 1H, NH), 7.88 (m, 6H, HPh y 6), 7.62 (m, 20H, HPh, 4, 3´, 4´, 5´), 7.14 (d, 1H, 
H3, 3JHH 8.3 Hz), 6.90 (m, 1H, H5). 31P{1H} NMR (400 MHz, (CD3)2CO)) δ: 64.8 (s, 1P, 
PPh2), 41.4 (s, 1P, PPh2). 
1H NMR (400 MHz, DMSO) δ: 9.19 (s, 1H, NH), 8.73 (m, 1H, H6), 7.86 (m, 1H, H4), 
7.57 (m, 24H, HPh), 7.03 (d, 1H, H3, 3JHH 8.3 Hz), 6.86 (m, 1H, H5). 19F NMR (400 
MHz, (CD3)2CO) δ: -80.05 (s, 1F, OTf). 31P{1H} NMR (400 MHz, (CD3)2CO) δ: 64.9 (s 
br, 1P, PPh2), 37.4 (s, 1P, PPh3). 13C{1H} NMR (300 MHz, DMSO) δ: 155.61 (s, 1C, 
C2), 151.69 (m, 1C, C6’), 147.50 (s, 1C, C6), 139.03 (s, 1C, C4), 137.76 (s, 1C, C4’), 
134.54 (d, 10C, CorthoPPh, 3JHH 10.4 Hz), 132.61 (s, 10C, CparaPh), 132.33 (s, 1C, C3’), 
129.80 (s, 5C, CmetaPh), 125.97 (s, 1C, C5’), 117.00 (s, 1C, C5), 112.77 (s, 1C, C3). MS 
(ESI+): m/z (%) = 738.2 ([M-OTf]+, 100), 723.2 ([(PPh2py)2Au]+, 49.4), 753.2 
([(PPh2NHpy)2Au]+, 25.8). 
 
Synthesis of [Au(PPh2NHpy)2](OTf) (5)  
 
To a solution of L1 (0.055 g, 0.2 mmol) in 20 mL of dichloromethane was added 
[Au(tht)2](OTf) (0.057 g, 0.11 mmol). The mixture was stirred for 2 h and then 
evaporation of the solvent to ca. 5 mL and addition of hexane gave complex 5 as a 
white solids. Yield: 0.077 g, 78.25 %. C35H30AuF3N4O3P2S (902.61): calcd. C, 46.57; 
H, 3.35; N, 6.21; S, 3.55, found C, 46.32; H, 3.52; N, 6.11; S, 3.91. IR (cm-1): ν(NH) = 
3243, ν(C=N) = 1591, ν(PN) = 901, νasym(SO3) = 1258, νsym(CF3) = 1218, νasym(CF3) = 
1166, νsym(SO3) = 1027. 1H NMR (400 MHz, DMSO) δ: 8.95 (s br, 1 H, NH), 7.75 (m, 1 
H, H6), 7.54 (m, 1 H, 11 H, HPh, y 4), 6.98 (m, 1 H, H3), 6.78 (m, 1 H, H5). 19F NMR (400 
MHz, DMSO) δ: -77.72 (s, 1F, OTf). 31P{1H} NMR (400 MHz, DMSO) δ: 62.3 (s, 1P, 
PPh2). 13C{1H} NMR (400 MHz, DMSO) δ: 156.00 (d, 1 C, C2, 2JCP 3.5 Hz), 146.76 (s, 
1 C, C6), 137.56 (s, 1 C, C4), 135.55 (d, 1 C, CipsoPh, 1JCP  37.0 Hz), 131.63 (d, 1 C, 
CorthoPh, 2JCP 17.0 Hz), 130.44 (s, 1 C, CparaPh), 128.36 (d, 1 C, CmetaPh, 3JCP 9.7 Hz), 
115.22 (s, 1 C, C5), 111.74 (d, 1 C, C3, 3JCP 2.4 Hz). MS (ESI+): m/z (%) = 753.2 ([M-
OTf]+, 100). 
 
Synthesis of [Ag(PPh2NHpy)2](OTf) (6) 
 
To a solution of L1 (0.055 g, 0.2 mmol) in 20 mL of dichloromethane was added 
Ag(OTf) (0.025 g, 0.1 mmol) or [Ag(tht)(OTf)] (0.034 g ,0.1 mmol.). The mixture was 
stirred for 1 h and then evaporation of the solvent to ca. 5 mL and addition of hexane 
gave complex 6 as a white solid. Yield: 0.134 g, 82.72 %. C33H30AgF3N4O3P2S 
(813.51): calcd. C, 51.67; H, 3.72; N, 6.89; S, 3.94, found C, 51.45; H, 3.89; N, 6.90; S, 
4.20. IR (cm-1): ν(NH) = 3243, ν(C=N) = 1592, ν(PN) = 902, νasym(SO3) = 1273 y 1250, 
νsym(CF3) = 1218, νasym(CF3) = 1152, νsym(SO3) = 1029. 1H NMR (400 MHz, (CD3)2CO) 
δ: 7.72 (m, 2H, NH y H6), 7.62 (m, 1H, H4), 7.47 (m, 6H, HPh), 7.34 (m, 4H, HPh), 7.04 
(d, 1H, H3, 3JHH 8.3 Hz), 6.90 (m, 1H, H5). 19F NMR (400 MHz, (CD3)2CO) δ: -80.07 (s, 
1F, OTf). 31P{1H} NMR (400 MHz, (CD3)2CO) δ: 29.9 (s, 1P, PPh2). 31P{1H} NMR, 
(400 MHz, (CD3)2CO, -70ºC) δ: 30.1 (2d, 2P, PPh2, J109Ag-P 398.8 Hz, J107Ag-P 347.5 Hz 
). 13C{1H} NMR (400 MHz, DMSO) δ: 156.63 (d, 1 C, C2,  2JCP 8.1 Hz), 147.14 (s, 1 C, 
C6), 138.67 (s, 1 C, C4), 134.90 (d, 1 C, CipsoPh, 1JCP 25.1 Hz), 131.36 (d, 1 C, CorthoPh, 
2JCP 18.9 Hz), 130.41 (s, 1 C, CparaPh), 128.66 (d, 1 C, CmetaPh, 3JCP 9.5 Hz), 115.44 (s, 1 
C, C5), 112.29 (s, 1 C, C3). MS (ESI+): m/z (%) = 665.0 ([M-OTf]+, 100). 
 
Synthesis of [Ag(PPh2NHpy)(OTf)] (7) 
 
To a solution of L1 (0.055 g, 0.2 mmol) in 25 mL of dichloromethane was added 
Ag(OTf) (0.051 g, 0.2 mmol). The mixture was stirred for 1 h and then evaporation of 
the solvent to ca. 5 mL and addition of hexane gave complex 7 as a white solid. Yield: 
0.083 g, 77.80 %. C18H15AgF3N2O3PS (535.23): calcd. C, 40.39; H, 2.82; N, 5.23; S, 
5.99, found C, 40.39; H, 2.92; N, 2.88; S, 5.71. IR (cm-1): ν(NH) = 3257, ν(C=N) = 
1591, ν(PN) = 916 νasym(SO3) = 1273 y 1241, νsym(CF3) = 1222, νasym(CF3) = 1155, y 
νsym(SO3) = 1024. 1H NMR (400 MHz, (CD3)2CO) δ: 8.24 (s br, 1H, NH ), 7.93 (m, 1H, 
H6), 7.76 (m, 5H, HPh ), 7.55 (m, 6H, HPh y 4), 7.18 (m, 1H, H3), 6.90 (m, 1H, H5). 19F 
NMR (400 MHz, (CD3)2CO) δ: -80.00 (s, 1F, OTf).  31P{1H} NMR (400 MHz, 
(CD3)2CO)) δ: 25.4 (s, 1P, PPh2). 31P{1H} NMR, (300 MHz, (CDCl3), -70ºC) δ: 24.8 
(2d, 1P, PPh2, J109Ag-P 493.9, J107Ag-P 427.9). 13C{1H} NMR (400 MHz, (CD3)2CO) δ: 
158.37 (s br, 1 C, C2), 149.37 (s br, 1 C, C6), 141.91 (s br, 1 C, C4), 135.85 (d, 1 C, 
CipsoPh, 1JCP 28.3 Hz), 133.73 (d ,6 C, CorthoPh, 2JCP 19.3 Hz), 130.09 (s, 3 C, CparaPh), 
130.02 (s, 6 C, CmetaPh, 3JCP 10.5 Hz), 118.37 (s, 1 C, C5), 115.20 (s br, 1 C, C3). 
 
Synthesis of [Ag(PPh3)n(PPh2NHpy)](OTf) (n= 1 (8), n= 2 (9)) 
 
To a solution of L1 (0.055 g, 0.2 mmol) in 20 mL of dichloromethane was added 
[Ag(OTf)(PPh3)] (0.104 g, 0.2 mmol.) or [Ag(OTf)(PPh3)2] (0.156 g, 0.2 mmol.). The 
mixture was stirred for 1 h and then evaporation of the solvent to ca. 5 mL and addition 
of hexane gave complexes 8 and 9 as white solid.  
Complex 8. Yield: 0.129 g, 81.10 %. C36H30AgF3N2O3P2S (797.51): calcd. C, 54.22; H, 
3.79; N, 5.31; S, 4.02, found C, 54.71; H, 3.92; N, 5.41; S,. 4.22. IR (cm-1): ν(NH) = 
3223, ν(C=N) = 1599, ν(PN) = 906, νasym(SO3) = 1282 y 1243, νsym(CF3) = 1218, 
νasym(CF3) = 1152, νsym(SO3) = 1027. 1H NMR (400 MHz, (CD3)2CO) δ: 8.22 (s br, 1H, 
NH), 7.87 (m, 1H, H6), 7.74 (m, 1 H, H4), 7.41 (m, 25H, HPh), 7.21 (d, 1H, H3, 3JHH 8.3 
Hz), 6.81 (m, 1H, H5). 19F NMR (400 MHz, (CD3)2CO) δ: -80.01 (s, 1F, OTf). 31P{1H} 
NMR (400 MHz, (CD3)2CO) δ: 25.6 (s, 1P, PPh2), 11.9 (s, 1P, PPh3). 31P{1H} NMR 
(300 MHz, (CD3)2CO), -70ºC) δ: 24.0 (2d, 1P, PPh2, J109Ag-P 490.5, J107Ag-P 425.8 Hz), 
9.16 (AB2 system, J109Ag-P 368.5, J107Ag-P 319.3, JAB 66.7 Hz). 13C{1H} NMR (300 MHz, 
DMSO) δ: 156.38 (s br, 1 C, C2), 146.98 (s, 1 C, C6), 138.89 (s, 1 C, C4), 134.18 (d, 1 C, 
CipsoPh, 1JCP 26.8 Hz), 132.66 (d, 1 C, CorthoPh, 2JCP 16.4 Hz), 131.14 (s, 1 C, CipsoPh), 
130.81 (d, 1 C, CorthoPh, 2JCP 18.4 Hz), 130.15 (s, 1 C, CparaPh), 128.61 (d, 1 C, CmetaPh, 
3JCP 9.3 Hz), 128.37 (d, 1 C, CmetaPh, 3JCP 6.7 Hz), 115.44 (s, 1 C, C5), 112.27 (s, 1 C, 
C3). MS (ESI+): m/z (%) = 647.00 ([M-OTf]+, 100). 
 
Complex 9. Yield: 0.179 g, 84.80 %. C54H45AgF3N2O3P3S (1059.80): calcd. C, 61.20; H, 
4.28; N, 2.64; S, 3.03, found C, 61.09; H, 4.30; N, 2.71; S, 3.46. IR (cm-1): ν(NH) = 
3199, νasym(SO3) = 1289 y 1244, νsym(CF3) = 1222, ν(C=N) = 1599, ν(PN) = 907, 
νasym(CF3) = 1152, νsym(SO3) = 1026. 1H NMR (300 MHz, (CD3)2CO) δ: 7.97 (s br, 1H, 
NH), 7.82 (m, 1H, H6), 7.67 (m, 1 H, H4), 7.44 (m, 4H, HPh), 7.11 (m, 27H, H3 y Ph), 
6.71 (m, 1H, H5). 19F NMR (400 MHz, (CD3)2CO) δ: -80.07 (s, 1F, OTf). 19F NMR (400 
MHz, (CD3)2CO) δ: -80.0 (s, 1F, OTf). 31P{1H} NMR (300 MHz, (CD3)2CO) δ: 26.2 (s, 
1P, PPh2), 8.5 (s, 2P, PPh3). 31P{1H} NMR (300 MHz, (CD3)2CO, -70ºC) δ: 9.9 y 9.3 
(2d), 23.9 y 21.8 (2m), (AB2 system, J109Ag-P 374.4, J107Ag-P 324.3, JAB 66.3 Hz). 
13C{1H} NMR (300 MHz, (CD3)2CO) δ: 159.16 (s br, 1 C, C2), 149.79 (s, 1 C, C6), 
141.13 (s, 1 C, C4), 137.19 (d, 1 C, CipsoPh, 1JCP 22.5 Hz), 135.28 (d, 1 C, CorthoPh, 2JCP 
16.3 Hz), 134.20 (1 C, CipsoPh, 1JCP 23.2 Hz), 133.13 (d, 1 C, CorthoPh, 2JCP 18.4 Hz), 
132.28 (s, 1 C, CparaPh), 132.20 (s, 1 C, CparaPh), 130.90 (d, 1 C, CmetaPh, 3JCP 9.2 Hz), 
130.59 (d, 1 C, CmetaPh, 3JCP 9.3 Hz), 118.02 (s, 1 C, C5), 114.85 (s, 1 C, C3). MS 





Synthesis of [Au(C6F5){PPh2NH(Htrz)}] (11) 
 
To a solution of L2 (0.053 g, 0.2 mmol) in 20 mL of dichloromethane was added 
[Au(C6F5)(tht)] (0.090 g, 0.2 mmol) The mixture was stirred for 1 h and then 
evaporation of the solvent to ca. 5 mL and addition of hexane gave complex 11 as a 
white solids. Yield: 0.092 g, 73.21 %. C20H13AuF5N4P (632.28): calcd. C, 37.99; H, 
2.07; N, 8.86, found C, 38.31; H, 2.43; N, 8.93. IR (cm-1): ν(NH) = 3231, ν(C=N) = 
1550, ν(PN) = 905, ν(C6F5) = 1500, 953, 793. 1H NMR (400 MHz, DMSO) δ: 13.41 (s 
br, 1H, NHtrz), 9.04 (s br,1H, NH-P), 8.25 (s br, 1H, H5), 7.77 (m, 4H, HPh), 7.59 (m, 
6H, HPh). 31P{1H} NMR (400 MHz, DMSO) δ: 68.9 (s, 1P, PPh2). 19F NMR (400 MHz, 
DMSO) δ: (-114.26)-(-114.82) (m, 2F, Fortho), -158.43 (t, 1F, Fpara, Jmeta-para = 21.21 
Hz,), (-161.51)- (-161.99) (m, 2F, Fmeta). MS (ESI+): m/z (%) = 632.9 ([M+H]+, 31.8). 
 
Synthesis of [Au{PPh2NH(Htrz)}2](OTf) (12) 
 
To a solution of L2 (0.053 g, 0.2 mmol) in 20 mL of dichloromethane was added 
[Au(tht)2](OTf) (0.057 g, 0.11 mmol). The mixture was stirred for 2 h and then 
evaporation of the solvent to ca. 5 mL and addition of hexane gave complex 12 as a 
white solids. Yield: 0.070 g, 79.86 %. C29H26AuF3N8O3P2S (882.54): calcd. C, 39.47; H, 
2.97; N, 12.70; S, 3.63, found C, 39.31; H, 2.98; N, 12.89; S, 3.44. IR (cm-1): ν(NH) = 
3313, ν(C=N) = 1585, ν(PN) = 1024, νasym(SO3) = 1288 y 1238, νsym(CF3) = 1220, 
νasym(CF3) = 1096, νsym(SO3) = 1024. 1H NMR (400 MHz, DMSO) δ: 13.55 (s br, 1H, 
NHtrz), 9.37 (s br,1H, NH-P), 8.33 (m, 1H, H5), 7.77 (m, 4 H, HPh), 7.60 (m, 7H, HPh). 
19F{1H} NMR (400 MHz, (CD3)2CO)) δ: -77.7 (s, 1F, OTf). 31P{1H} NMR (400 MHz, 
DMSO) δ: 68.7 (s, 1P, PPh2). MS (ESI+): m/z (%) = 733.2 ([M-OTf]+, 100). 
 
Synthesis of Ag{PPh2NH(Htrz)}](OTf) (13) and [Ag{PPh2NH(Htrz)}2](OTf) (14). 
 
To a solution of L2 (0.053 g, 0.2 mmol) in 20 mL of dichloromethane was added 
Ag(OTf) (0.025 g, 0.1 mmol or 0.05 g, 0.2 mmol) or [Ag(tht)(OTf)] (0.069 g, 0.2 
mmol). The mixture was stirred for 1 h and then evaporation of the solvent to ca. 5 mL 
and addition of hexane gave complexes 13 and 14 as white solids.  
 
Complex 13. Yield: 0.076 g, 73.20 %. C15H13AgF3N4O3PS (525.19): calcd. C, 34.30; H, 
2.49; N, 10.67; S, 6.11, found C, 34.77; H, 2,49; N, 10.83, S, 6.42. IR (cm-1): ν(NH) = 
3207, ν(C=N) = 1570, ν(PN) = 932, νasym(SO3) = 1272 y 1243, νsym(CF3) = 1223, ν(CF3) 
= 1024, νsym(SO3) = 981. 1H NMR (400 MHz, DMSO) δ: 13.63 (s br, 1H, NHtrz), 8.80 
(s br,1H, NH-P), 8.44 (s br, 1H, H5), 7.52 (m, 10H, HPh). 19F NMR (400 MHz, DMSO) 
δ: -77.73 (s, 1F, OTf). 31P{1H} NMR (400 MHz, (CD3)2CO)) δ: 37.3 (s, 1P, PPh2).  
 
Complex 14. Yield: 0.060 g, 76.0 %. C29H26AgF3N8O3P2S (793.44): calcd. C, 43.90; H, 
3.30; N, 14.12; S, 4.04, found C, 43.62; H, 3.29; N, 14.47, S, 4.38. IR (cm-1): ν(NH) = 
3180, ν(C=N) = 1565, ν(PN) = 922, νasym(SO3) = 1276 y 1234, νsym(CF3) = 1170, ν(CF3) 
= 1100, νsym(SO3) = 1029. 1H NMR (400 MHz, DMSO) δ: 13.70 (s br, 1H, NHtrz), 9.08 
(s br,1H, NH-P), 8.45 (s br, 1H, H5), 7.52 (m, 10 H, HPh).  19F NMR (400 MHz, DMSO) 
δ: -80.31 (s, 1F, OTf). 31P{1H} NMR (400 MHz, DMSO) δ: 40.8 (s, 2P, PPh2). 31P{1H} 
NMR (300 MHz, CDCl3, -70ºC) δ: 38.6 (2m, 2P, PPh2, J109Ag-P 472.2 Hz, J107Ag-P 413.4 
Hz). MS (ESI+): m/z (%) = 644.3 ([M-OTf]+, 31.6). 
 
 
4.1.3. Crystal Structure Determinations 
 
Data were recorded with a Bruker Smart 1000 CCD (6) or Oxford Diffraction Xcalibur 
(9) diffractometer. The crystals were mounted in inert oil on glass fibres and transferred 
to the cold gas stream of the diffractometer. Data were collected by using 
monochromated Mo-Kα radiation (λ = 0.71073 Å) in ω-scans. Absorption corrections 
based on multiples cans were applied by using the SADABS program [63] for complex 
6 and using spherical harmonics implemented in SCALE3 ABSPACK scaling algorithm 
for complex 9.The structures were solved by direct methods and refined on F2 by using 
the SHELXL-97 program [64]. All non-hydrogen atoms were refined anisotropically. 
Hydrogen atoms were included by using a riding model. Further crystal data are given 
in Table 4. CCDC-1027814 (6) and 1027815 (9) contains the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from The 




4.2. Antibacterial assays 
Determination of bacterial growth inhibition by the disc diffusion method was 
performed by culturing bacteria in the appropriate solid media. LB- or BHI-agar plates 
were used for Gram –negative or Gram-positive bacteria respectively. After inoculation 
of bacterial cultures, sterile cellulose discs containing 5-fold serial dilutions of the tested 
compounds (or control antibiotics) were placed onto the agar. Plates were incubated at 
37ºC for 24 hours to examine growth inhibition zones. MIC values were calculated by 
observing bacterial growth inhibition in liquid cultures. LB or BHI liquid media was 
inoculated with 5-fold serial dilutions of the tested compounds and subsequently, tubes 
were inoculated with equal volumes of the corresponding bacteria and incubated for 24 
hours at 37ºC. Culture density was determined by Abs at 600 nm and compared to 
control cultures in the absence of compounds. Those cultures showing inhibition of 
bacterial growth were plated on the appropriate solid media to determine the MBC. 
After 24 hours incubation at 37ºC, colony forming units were enumerated and compared 



































cfu Colony Forming Unit 
Cm Chloramphenicol 
CDCl3 Chloroform 
(CD3)2CO Acetone  




MBC Minimum Bactericidal Concentration 
MIC Minimum Inhibitory Concentration 
Km Kanamycin 
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Amp  100 µg/ml (0.3 mM )  10  10  
Km  50 µg/ml (0.1 mM )  ‐  9   
Gm  100 µg/ml (0.2 mM)  11  11  
Cm  30 µg/ml (9.2x10‐2 mM)  ‐  10  
Complex  25 mM  12.50 mM  6.25 mM  3.12 mM  25 mM  12.50 mM  6.25 mM  3.12 mM 
1   ‐  ‐  ‐  ‐  Thin line  Thin line  1  1 
3   ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 
8   ‐  ‐  ‐  ‐  ‐       
  50 mM    25 mM  12.50 mM  6.25 mM  50 mM  25 mM  12.50 mM    6.25 mM 
4   ‐  ‐  ‐  ‐  ‐  ‐     
6   ‐  ‐  ‐  ‐  ‐  ‐     
9   ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 
10   ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 
11                  
13   1  1  1  1  1  1  1  1 





Amp  100 µg/ml (0.3 mM)  19  Amp  100 µg/ml (0.3 mM )  ‐ 
Gm  50 µg/ml (0.1 mM)  11  Rif  0.5 µg/ml (6x10‐4 mM)  ‐ 
Van  10 µg/ml (6.9x10‐3 mM)  1  Van  10 µg/ml (6.9x10‐3 mM)  12.5 
Ery  10 µg/ml (1.3 x10‐2 mM)  14  DMSO  neat  ‐ 
Complex  25 mM  12.50 mM  6.25 mM  3.12 mM  25 mM  12.50 mM  6.25 mM  3.12 mM 
1   19  16  15  14  15  14  13  12 
3   14  13  12  11  12  12.5  10  9 
8   Thin line  Thin line  Thin line  Thin line  1  Thin line  1  Thin line 
  50 mM    25 mM  12.50 mM  6.25 mM  50 mM  25 mM  12.50 mM    6.25 mM 
4   8  8  9  9  11  11  11  11 
6   1  1  1  1  1  1  1  1 
9   Thin line  Thin line  Thin line  Thin line  ‐  ‐  ‐  ‐ 
10   10  17  17  16  15  14  15  15 
11   19  11  11  12  14  14  14  14 
13   10  10  10  9  ‐  ‐  ‐  ‐ 















Complex  MIC (mM)  MBC (mM)  MIC (mM) MBC (mM) MIC (mM) MBC (mM) MIC (mM)  MBC (mM)
1  0.1  NT  0.1 > 0.1 ‐ ‐ ‐  ‐
3  ‐  ‐  ‐ ‐ ‐ ‐ ‐  ‐
4  0.2  0.2  0.2 5 ‐ ‐ ‐  ‐
10  0.2  NT  0.2 NT ‐ ‐ ‐  ‐
11  0.2  NT  0.2 NT ‐ ‐ ‐  ‐
13  1  NT  1 5 1 1 ‐  ‐
14  5  5  5 5 1 > 1 ‐  ‐
Scheme and Figure Captions 
 
Scheme  1.  Synthesis  of  gold(I)  and  silver(I)  complexes with  Ph2PNHpy  (L1).  i)  [AuX(tht)];  ii) 











Fig.  3.  Structure  of  the  cation  of  complex  [Ag(Ph2PNHpy)(PPh3)2](OTf)  (9).  Selected  bond 
lengths (Å) and angles for one of the independent molecules (°): Ag(1)‐N(2) 2.405(5), Ag(1)‐P(2)                    
2.4523(16),  Ag(1)‐P(3)  2.4650(15),  Ag(1)‐P(1)  2.4948(16);  N(2)‐Ag(1)‐P(2)  108.66(12),  N(2)‐
Ag(1)‐P(3)  110.11(12),  P(2)‐Ag(1)‐P(3)  119.42(5),  N(2)‐Ag(1)‐P(1)  74.99(12),  P(2)‐Ag(1)‐P(1)             
121.63(6), P(3)‐Ag(1)‐P(1) 112.26(6).   
Fig. 4. Antibiotics structures used as control drugs. 
Fig. 5. Zones inhibition of complexes in disc diffusion. Plate A: S. typhimurium SV5015, plate B: 
E. coli ATCC 10536; plate C: S. Aureus ATCC 11632, plate D: L. monocytogenes EGD‐e. First line: 
control antibiotics (from left to right, plate A and B: Amp, Km, Gm, Cm; plate C: Amp, Gm, Van, 
Ery; plate D: Amp, Rif, Van, DMSO), second line: complex 11, third line: complex 10, fourth line: 
complex 14. Concentrations from left to right: 50, 25, 12.5, 6.25 mM. 
 
 
 
 
 
 
